FDA Advisors Split on Regimens for Breast, Prostate Cancers

Published Date: 13 May 2026

The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.

2.

Early-Onset Colorectal Cancer in Male Veterans is Predicted by Risk Factors.

3.

Toxic fungus from King Tutankhamun's tomb yields cancer-fighting compounds—new study

4.

According to a study, there is now a 94 percent survival rate for children with acute lymphatic leukemia.

5.

Morning Immunotherapy Does Not Boost Lung Cancer Survival


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot